Related Experiment Videos
Serum lysozyme in Crohn's disease and ulcerative colitis
South African Medical Journal = Suid-Afrikaanse Tydskrif Vir Geneeskunde
|December 17, 1977
Summary
Serum lysozyme (muramidase) levels are elevated in active Crohn's disease and pulmonary tuberculosis. These elevated enzyme levels may help differentiate Crohn's disease from ulcerative colitis, but tuberculosis must be ruled out.
Area of Science:
- Biochemistry
- Immunology
- Gastroenterology
Background:
- Inflammatory bowel disease (IBD) encompasses Crohn's disease and ulcerative colitis, both characterized by chronic inflammation.
- Serum lysozyme (muramidase) is an enzyme with antimicrobial properties, and its levels can be altered in various inflammatory conditions.
- Pulmonary tuberculosis is an infectious disease that can also influence systemic inflammatory markers.
Purpose of the Study:
- To investigate serum lysozyme concentrations in patients with inflammatory bowel disease (IBD) and pulmonary tuberculosis.
- To assess the potential of serum lysozyme as a biomarker for differentiating between Crohn's disease and ulcerative colitis.
- To evaluate serum lysozyme levels as an indicator of disease activity in Crohn's disease.
Main Methods:
- Serum lysozyme concentrations were measured in 55 IBD patients, 6 with miscellaneous bowel disease, 40 with pulmonary tuberculosis, and 20 healthy controls.
- Statistical analysis was performed to compare mean lysozyme levels across different patient groups and controls.
- P-values were used to determine the statistical significance of observed differences in enzyme concentrations.
Main Results:
- Mean serum lysozyme levels were significantly higher in patients with active Crohn's disease (20.77 +/- 2.17 microgram/ml) compared to ulcerative colitis (9.61 +/- 1.02 microgram/ml) and normal controls (6.95 +/- 0.36 microgram/ml).
- Patients with sputum-negative (13.05 +/- 1.06 microgram/ml) and sputum-positive (20.35 +/- 2.08 microgram/ml) tuberculosis also exhibited elevated serum lysozyme levels.
- While elevated in active Crohn's disease, serum lysozyme levels showed some overlap with those in ulcerative colitis and tuberculosis.
Conclusions:
- Serum lysozyme levels may serve as a useful biomarker for distinguishing active Crohn's disease from ulcerative colitis, although overlap exists.
- Elevated serum lysozyme concentrations in patients with pulmonary tuberculosis necessitate its exclusion when considering lysozyme as a diagnostic marker for IBD.
- Serum lysozyme levels could potentially be a valuable index for monitoring disease activity in patients with Crohn's disease.